Summary

Eligibility
for people ages 40-70 (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

Official Title

A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Keywords

Chronic Obstructive Pulmonary Disease, Lung Diseases, Obstructive Lung Diseases, Inflammation, Itepekimab SAR440340, Itepekimab

Eligibility

Locations

  • UCLA Medical Center - Harbor- Site Number : 8400006
    Torrance California 90509 United States
  • National Jewish Health Medical Center- Site Number : 8400012
    Denver Colorado 80206 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Sanofi
ID
NCT05326412
Phase
Phase 2 Chronic Obstructive Pulmonary Disease Research Study
Study Type
Interventional
Participants
About 49 people participating
Last Updated